The ANXA8 antibody targets Annexin A8 (ANXA8), a member of the annexin family of calcium-dependent phospholipid-binding proteins. Annexins are involved in diverse cellular processes, including membrane organization, vesicle trafficking, and cell signaling. ANXA8. specifically, is characterized by its unique N-terminal domain and calcium-dependent binding to cellular membranes. It is expressed in various tissues, with higher levels observed in the placenta, skin, and certain immune cells, and has been implicated in cell differentiation, apoptosis, and inflammatory responses.
Research on ANXA8 has highlighted its dual role in cancer. In some contexts, such as acute myeloid leukemia (AML) and pancreatic cancer, ANXA8 overexpression correlates with tumor progression, metastasis, and poor prognosis, suggesting its potential as a diagnostic or prognostic biomarker. Conversely, in other cancers like breast cancer, reduced ANXA8 expression has been linked to aggressive phenotypes, indicating context-dependent functions. ANXA8 antibodies are critical tools for studying these mechanisms, enabling detection of protein expression via techniques like immunohistochemistry (IHC), Western blotting (WB), and immunofluorescence (IF).
Commercially available ANXA8 antibodies are typically monoclonal or polyclonal, validated for specificity and sensitivity across applications. Recent studies also explore ANXA8's role in modulating the tumor microenvironment and chemoresistance, expanding its relevance in therapeutic targeting. However, variability in ANXA8 expression across cancer types underscores the need for further research to clarify its molecular interactions and clinical utility.